Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Research purpose Using single-cell sequencing, 3D/4D genomics and multidimensional omics technologies to reveal the complex cellular and molecular regulatory networks of cardiovascular and nervous system diseases, unique phenotypic changes of specific cell types, and different gene expression patterns, identify cell types and cell subsets associated with cardiovascular and nervous system diseases, and discover disease-related genes. To reveal new pathological mechanisms of related diseases and develop new diagnosis and treatment methods. Research background Cardiovascular and nervous system diseases such as arrhythmias (atrial fibrillation, ventricular tachycardia, ventricular fibrillation, postoperative vascular stenosis injury, etc.), heart failure, atherosclerosis (coronary heart disease, stroke, peripheral vascular disease, carotid atherosclerosis, etc.), epilepsy, moyamoya disease, etc., are currently leading to the main diseases affecting the health and death of residents in China. The data integration method based on single-cell sequencing, multi-omics data, and machine learning to analyze molecular level changes in cardiovascular and nervous system-related diseases can help deepen the research on the pathogenesis of cardiovascular and nervous system-related diseases and provide new ideas for the prevention and treatment of related diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Inclusion criteria for patients with valvular atrial fibrillation:

• Moderate or above mitral valve disease; The occurrence of atrial fibrillation was recorded by 12-lead electrocardiogram or 24-hour holter electrocardiogram. 3.18≤ Age ≤75 years old.

• Inclusion criteria for disease control of valvular atrial fibrillation:

• No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.

• Inclusion criteria for carotid atherosclerosis cases:

• Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.

• Inclusion criteria for carotid atherosclerosis control:

• The inclusion criteria for carotid atherosclerosis cases were met. The peripheral tissue of the vascular plaque was discarded in the same patient.

• Inclusion criteria for moyamoya disease cases:

• Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.

• Moyamoya disease control inclusion criteria:

⁃ Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.

Locations
Other Locations
China
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
RECRUITING
Jinan
Contact Information
Primary
Xin Tao, Director of Neurosurgery
drxintao@yeah.net
18888376796
Time Frame
Start Date: 2023-04-01
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 400
Treatments
Disease group
Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease)
Healthy control group
Sponsors
Leads: Tao Xin

This content was sourced from clinicaltrials.gov